Pancreas cancer is one of the most lethal malignancies and is characterized by activating mutations of Kras, present in 95% of patients. More than 60% of pancreatic cancers also display increased c-Src activity, which is associated with poor prognosis. Although loss of tumor suppressor function (for example, p16, p53, Smad4) combined with oncogenic Kras signaling has been shown to accelerate pancreatic duct carcinogenesis, it is unclear whether elevated Src activity contributes to Kras-dependent tumorigenesis or is simply a biomarker of disease progression. Here, we demonstrate that in the context of oncogenic Kras, activation of c-Src through deletion of C-terminal Src kinase (CSK) results in the development of invasive pancreatic ductal adenocarcinoma (PDA) by 5-8 weeks. In contrast, deletion of CSK alone fails to induce neoplasia, while oncogenic Kras expression yields PDA at low frequency after a latency of 12 months. Analysis of cell lines derived from Ras/Src-induced PDA's indicates that oncogenic Ras/Src cooperativity may lead to genomic instability, yet Ras/Src-driven tumor cells remain dependent on Src signaling and as such, Src inhibition suppresses growth of Ras/Src-driven tumors. These findings demonstrate that oncogenic Ras/Src cooperate to accelerate PDA onset and support further studies of Src-directed therapies in pancreatic cancer.
Introduction
Almost a century ago, Peyton Rous reported the discovery of a 'transmissible tumor-causing particle' that produced sarcomas when injected into chickens (Rous, 1911) . This early description of the Rous sarcoma virus set the stage for the identification of the first oncogene, v-Src, some 60 years later. Studies by Varmus, Bishop, Vogt and colleagues in the 1970's established that expression of the Src retroviral oncoprotein was sufficient to transform avian cells and also promote sarcoma formation in chickens (Martin, 2001) . Subsequently, the cellular counterpart, c-Src was characterized as the founding member of the Src family of protein tyrosine kinases (SFKs) (Stehelin et al., 1976; Hunter and Sefton, 1980) . Since that time, Src kinase has been intrinsically linked with cellular transformation and changes in its activity impact proliferation, invasion and migration (Bromann et al., 2004) . More recently, a number of studies utilizing in vivo orthotopic transplantation models have not only underscored the importance of Src activity during tumorigenesis, but also provided compelling support for Src as a therapeutic target (Yezhelyev et al., 2004; Rucci et al., 2006; Trevino et al., 2006; Koreckij et al., 2009; Vitali et al., 2009) . In addition to its direct effects on the properties of a tumor cell, Src can also indirectly modulate neoplasia through its role in tumor-associated processes such as angiogenesis and vascular permeability, yet the precise role of Src during the development of malignancy remains unclear (Eliceiri et al., 1999) .
Overexpression or activation of Src kinase has been described in many human cancers including those of the colon, breast, lung, liver, head and neck, and brain and pancreas (Irby and Yeatman, 2000; Ishizawar and Parsons, 2004) . Furthermore, Src kinase activity has been shown to increase as a function of tumor progression, implicating Src in the transition to malignancy (Talamonti et al., 1993) . As Src activity is tightly controlled posttranslationally, deregulation at this level can lead to an increase in oncogenic potential. Src activation can occur following a loss of regulation at its inhibitory C-terminal tyrosine residue (Tyr-529 in mouse, Tyr-530 in humans) due to reduced C-terminal Src kinase (CSK) abundance, elevated phosphatase activity or altered CSK-binding protein function (Irby and Yeatman, 2000) . Loss of Tyr-529 phosphorylation leads to autophosphorylation at Tyr-418 (mouse)/Tyr-419 (human) and activation of Src. Alternatively, Src can be activated as a consequence of elevated signaling from the upstream receptor tyrosine kinases, epidermal growth factor receptor, RON, IGF-1R and c-Met, as well as the chemokine receptor, CXCR4 and integrins such as avb3, each of which have been implicated in carcinogenesis (Barton et al., 1991; Billadeau et al., 2006; Thomas et al., 2007; Desgrosellier et al., 2009; Ricono et al., 2009) .
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignancies, causing more than 200 000 deaths worldwide annually. Despite advances in our understanding of the genetic basis of PDA, the 5-year survival rate for patients diagnosed with the disease in 2009 remains less than 5% (Warshaw and Fernandezdel Castillo, 1992; Jemal et al., 2009) . Elevated Src levels have been reported in more than 70% of patients with ductal adenocarcinoma of the pancreas and more than 60% of pancreatic tumors show increased Src activity (Lutz et al., 1998; Morton et al., 2010) . Furthermore, increases in Src protein and activity are associated with vascular invasion, lymph node positivity and diminished survival (Morton et al., 2010) . To test the hypothesis that heightened Src activity may contribute to PDA progression, we used floxed CSK mice as a tool to enable deletion of the inhibitory kinase, CSK, resulting in concomitant activation of the Src family kinases in the embryonic pancreas. We were particularly interested in the consequences of Src activation in the context of oncogenic Kras signaling as B95% of PDA patients harbor Kras mutations at diagnosis (Almoguera et al., 1988) . Previous studies have documented that loss of tumor suppressors such as p16, p53, Smad4 or TGFbeta receptor 2, dramatically accelerates the development of Kras-dependent PDA in mice (Aguirre et al., 2003; Hingorani et al., 2005; Bardeesy et al., 2006; Ijichi et al., 2006; Izeradjene et al., 2007) . Here, we show that CSK deletion and activation of c-Src dramatically accelerates both the onset of precursor lesions initiated by oncogenic Kras signaling as well as the progression to invasive adenocarcinoma. These findings support a role for Src kinase activity in Kras
G12D
-dependent pancreatic neoplasia, and provide a model system to study the role of Src in pancreatic tumorigenesis.
Results

Activation of Src kinase is an early event in pancreas cancer
To ascertain the activation status of the SFKs during the development of PDA, we performed immunohistochemistry analysis on primary tumor specimens from PDA patients using an antibody that recognizes the phosphorylated (Y419 in human, Y418 in mouse), active form of each member of the Src-family kinases. Strong phospho-SFK (Y419) staining, denoting an active SFK enzyme, was evident in the neoplastic ducts of more than 60% (14/21) of the patient tumor specimens (Figure 1 ), but undetectable or present at low levels in the adjacent non-neoplastic ductal epithelium (Figures 1a  and b) . We noted strong pSFK(Y419) staining not only in the primary tumor (Figures 1e and f) , but also in adjacent pancreatic intraepithelial neoplasia (Figures 1a  and d) , which suggests that SFK activation may be an early event in pancreatic tumorigenesis. These data corroborate a recent study describing elevated Src activity in human pancreas cancer (Morton et al., 2010) . Given that Kras mutations are the earliest identifiable genetic alterations in PDA, we became particularly interested in the question of whether elevated SFK signaling might cooperate with oncogenic Kras to promote pancreatic neoplasia.
Dual Ras/SFK activation cooperate to promote PDA To determine the role of activated SFK signaling in the onset and progression of Kras G12D initiated neoplasia, we targeted oncogenic Kras G12D expression and homozygous deletion of the SFK inhibitor, CSK to the embryonic pancreas using Pdx1-Cre-driven recombination (Figure 2a) . Allele-specific genotyping confirmed the genetic composition of the compound LSL-Kras Figure S1) (Hingorani et al., 2003) . Deletion of pancreatic CSK alone did not impair pancreatic development indicating that CSK is not required for normal development of this organ. Most significantly, none of the CSK f/f ;Pdx1-Cre animals harbored neoplastic lesions at the time of necropsy (up to 60 weeks of age, n ¼ 25 mice; Supplementary Figure S3 ). These findings demonstrate that CSK deletion alone is insufficient to initiate neoplasia and that oncogenic Kras and SFK activation can cooperate to accelerate the development of PDA in mice.
Immunohistochemical analysis of tumors from LSL-Kras
G12D
;CSK f/f ;Pdx1-Cre mice confirmed the absence of CSK and the activation of the Src family kinases, as measured by phospho-SFK (Y418) staining in the neoplastic ducts (Figure 4a) . Activation of the MAP kinase pathway was demonstrated by strong phosphoErk staining in the ductal epithelium (Figure 4a ). By contrast, Src and Erk are not activated in the nonneoplastic pancreas (Figure 4a) . Src, Yes, Fyn and Lyn have each been implicated in neoplastic transformation of sites such as the pancreas, prostate and breast. To define the SFKs that are activated in this model, we developed cell lines from the murine PDA's ( Figure 4b) . Src was the predominant active SFK in the lysates of tumor-derived cell lines, with Yes displaying minimal levels of activity (Figure 4b ). Lyn and Fyn activity were undetectable (data not shown).
Ras/Src derived PDA displays features of the human disease To further characterize the oncogenic cooperativity between Kras G12D and activated c-Src, we investigated the kinetics of tumor formation and the stromal/ epithelial organization in the pancreata of compound mutant mice. Ductal hyper-proliferation was evident throughout the pancreas as early as the sucklingweaning transition (3 weeks) ( Figure 3c ). By 5 weeks, the pancreata were characterized by multiple foci of carcinoma, most of which were poorly differentiated, but which also included some moderately to well differentiated neoplastic ducts (Figures 3c and f) . 
Oncogenic Ras/Src cooperativity DJ Shields et al
We did not detect visceral metastases to the liver or lungs, which could be due to a requirement for additional genetic lesions and/or the locally aggressive nature of the disease denying time for the formation of distant disease.
Marked stromal hyperplasia and fibroblast infiltration was observed in the Ras/Src-driven tumors, a known feature of human tumors (Hernandez-Munoz et al., 2008) (Figure 3 ) and in fact, the surrounding stroma commonly featured a higher number of proliferating cells than the neoplastic ductal epithelium (Figure 5d ). This led to highly fibrous tumors that were frequently palpable through the abdominal wall and had a firm consistency at the time of necropsy. This could be attributed, at least in part, to the significant levels of collagen deposition throughout the tumor, as visualized by multispectral, birefringence imaging (Figure 5e ). The surrounding stroma was also characterized by high levels of desmin expression, distinguishing it clearly from the invading carcinomatous glands (Figure 5f ).
Oncogenic Ras/Src cooperativity and genomic instability Next, we sought to characterize the underlying mechanisms of Src/Ras-driven tumorigenesis in this model. One of the hallmarks of PDA is genomic instability (Hezel et al., 2006) , and in our analysis of the tumor-derived Kras/Src cells, we noted multiple examples of abnormal mitotic spindles and centrosomal amplification, as observed by immunofluorescence analysis of a-tubulin and g-tubulin, respectively (Supplementary Figure S4A-B) . Furthermore, LaminB staining of the nuclear envelope in these cells enabled the identification of discrete micronuclei (MN) (Figure 6a ), which are established markers of genomic instability resulting from chromosomal malsegregation (Fenech, 2000 (Figure 6c ). These findings suggest that in combination with oncogenic Kras, Src activation can promote the onset of genomic instability, a hallmark of malignant disease.
Tumor cells exhibit signs of Src dependency
As combined Src/Ras activation may promote genetic instability, which in turn may lead to differential tumor suppressor loss, the question arises as to whether secondary genetic lesions become the drivers of tumorigenicity in the Kras/Src cells, or if the cells remain dependent on activated Src signaling. To address this question, we reintroduced CSK to Kras/Src cells and performed anchorage-independent growth assays. Importantly, reconstitution with CSK significantly reduced colony formation in soft agar whereas a kinase-dead version of CSK had no effect on colony formation in this assay (Figure 7a ). In contrast, expression of either wild-type CSK or the kinase-dead derivative did not impair the colony-forming ability of Kras cells (Figure 7a ), which express oncogenic Kras in the context of wild-type (non-activated) Src. These findings indicate that the Kras/Src cells exhibit a dependence on Src and might be sensitive to pharmacological inhibitors of Src.
Dasatinib is a small molecule Src/Abl inhibitor that was originally approved to treat imatinib (Gleevec)-resistant chronic myeloid leukemia patients (Lombardo et al., 2004) and is currently in trials against a plethora of solid tumors. To assess the sensitivity of the Kras/Src tumor-derived cell lines to Src blockade, we initially Figure S5 , IC50 ¼ 47.6 nM), at a dose required to achieve inhibition of Src kinase signaling in these cells (Supplementary Figure S6) . Next, to evaluate the consequences of Src kinase inhibition on tumorigenesis in vivo, Kras/Src cells were orthotopically injected into the pancreas of 8-week-old nu/nu mice. After 7 days of tumor growth, animals were systemically treated with dasatinib (25 mg/kg, p.o., qd Â 14) and tumors were resected and analyzed on day 21. Dasatinib treatment caused a significant reduction (50%) in tumor burden (P ¼ 0.0019, n ¼ 9 mice/treatment group) relative to tumors in vehicle-treated mice (Figure 7b ). Significantly, dasatinib had no effect on the growth of tumors derived from Kras cells, which express Kras G12D in the context of significantly lower levels of activated Src kinase than Kras/Src cells (Figures 4b and 7b) . Dasatinib treatment caused a significant reduction in Src activation in the Kras/Src tumors (Figure 7c, upper) , and while immunohistochemical analysis of the orthotopic tumors demonstrated that Src activity was most markedly reduced in the neoplastic ducts, a reduction in Src activity in the surrounding stroma was also observed (Figure 7c, lower) . These studies suggest that Src activity, in concert with oncogenic Kras, has a key role in the growth of these tumors, and provide support for the inherent Src dependency of these cells.
Discussion
A novel role for Src activation in pancreatic neoplasia
Accumulating evidence from xenograft and orthotopic studies has strongly implicated Src in tumorigenesis and metastasis. However, data from genetically engineered mouse models had indicated that Src activation alone may be insufficient for tumor initiation. For example, overexpression of oncogenic v-Src in astrocytes leads to the development of astrocytomas, but the latency is long (65 weeks) and the penetrance is low as only 14% of mice develop tumors (Maddalena et al., 1999) . Similarly, overexpression of SrcA(Y530F), wild-type c-Src or deletion of CSK in keratinocytes each promotes epidermal hyperplasia, but a secondary insult such as wounding, or exposure to a combination of carcinogens 7,12-dimethylbenz(a)anthracene (DMBA) and promoting agents 12-O-tetradecanoylphorbol-13-acetate (TPA) is required for carcinoma development (Matsumoto et al., 2004) . In a more recent study, global overexpression of the human c-Src gene yielded neoplastic lesions after 20 months, but again, only 15% of the mice Oncogenic Ras/Src cooperativity DJ Shields et al were affected (Kline et al., 2008) . Intercrossing with p21 null mice increased the incidence to 26% at 14 months (Kline et al., 2008) , suggesting that additional genetic events may enable the oncogenic potential of Src kinase.
Cooperative Kras/Src signaling in the development of PDA Here, we show that cooperative signaling between Kras G12D and activated Src promotes rapid development of aggressive pancreatic cancer. Although oncogenic cooperativity has been documented previously between proteins such as c-Myc and Bcl-2 in lymphoid tumors (Fanidi et al., 1992) , as well as between mutant Kras and c-Myc in mammary carcinogenesis (Podsypanina et al., 2008) , this is, to our knowledge, the first demonstration that oncogenic cooperation between activated Kras/Src can promote neoplasia in the mouse. Importantly, oncogenic Ras/Src cross-talk had previously been demonstrated in Drosophila (Vidal et al., 2006) , suggesting that cooperative signaling between these two classical oncoproteins may not be restricted to pancreatic carcinomas.
Deletion of CSK alone was insufficient to initiate carcinogenesis, but combined Ras activation and CSK deletion leading to activation of Src led to the development of PDA by 5-8 weeks of age, as compared * * Figure 5 The epithelial and stromal sub-compartments of LSL-Kras G12D ;CSK f/f ;Pdx1-Cre tumors share many features in common with human pancreatic carcinoma. Both infiltrating carcinoma and precursor lesions display strong expression of the ductal marker, CK-19 (a). Acidic and neutral mucin content of infiltrating neoplastic ducts (large arrows) was demonstrated by alcian blue (b) and periodic acid Schiff (c) staining, respectively. Proliferative cells were evident in both the stroma (asterisk) and neoplastic epithelium (arrow) of invasive carcinomas as demonstrated by Ki-67 staining (d). Collagen deposition (green) can be detected by multispectral birefringence imaging (e), whereas strong desmin staining also identified the abundant fibroblast content (f).
with 12-14 months for Kras alone, establishing that in the context of oncogenic Kras, activated Src kinase signaling can act as a promoter of tumor progression. Loss of CSK function can lead to the activation of each of the Src family kinase members but in this model, c-Src was the only SFK member activated in tumors with oncogenic Kras expression and CSK loss. However, this does not rule out a possible role for other as yet unidentified CSK substrates in the progression of Kras-dependent PDA. Similarly, CSK loss may impact the function of key interactants, such as the p53 binding protein ASPP. Additional studies will be necessary to define the precise role of CSK and Src in pancreas cancer progression.
In recent years, a number of other spontaneous mouse models of pancreatic cancer have been generated based on the known genetic lesions in PDA patients. Although mutational activation of oncogenic Kras has been established as a key initiating event, additional driver events that contribute to disease progression include the silencing or deletion of Ink4a/Arf (80-85% of clinical PDA specimens), mutational inactivation of p53 (65%) and the homozygous deletion of Dpc4/Smad4 (55%) (Hezel et al., 2006) . So, how might changes in Src activity interplay with these other key genetic lesions in pancreatic neoplasia? v-Src was the first identified oncogene, but activating mutations of c-Src are extremely rare in human cancers and none have been detected in PDA. Despite this, Src activity is increased in 60% of PDA's and this is likely due to increased Src protein abundance or elevated signaling from activated RTK's such as ErbB-2 (Her2-Neu) and RON (Thomas et al., 2007; Ricono et al., 2009) . In fact, members of the epidermal growth factor receptor family are overexpressed in up to 70% of PDA's (Hall et al., 1990) , and upregulation of ErbB-2 is believed to be one of the earliest events in neoplastic conversion of the pancreas (Hruban et al., 2000) . Genetic ablation of Ink4a/Arf in the context of oncogenic Kras signaling leads to a murine model of metastatic PDA that recapitulates features of the human disease (Aguirre et al., 2003) . Intriguingly, this combination of mutations also leads to a significant upregulation of epidermal growth factor receptor and Her2 expression in the neoplastic ducts, each of which can activate Src kinase. More recently, analysis of tumors from the LSL-Kras G12D ; LSLp53 R172H ;Pdx1-Cre mouse model, which closely recapitulates many clinical features of the disease, demonstrated that Src activity is elevated in the pancreatic intraepithelial neoplasia lesions and continues to increase as a function of disease progression in this model (Morton et al., 2010) . Furthermore, progression to advanced metastatic disease was attenuated by systemic Src inhibition (Morton et al., 2010) .
A model of Src dependency
Conversely, data from our model suggest that Ras activation combined with CSK deletion may actually promote genetic instability, which, in turn, could lead to loss of key tumor suppressors such as p16, p53 and Smad4. These findings are consistent with previous reports showing that Src/MAPK signaling promotes genomic instability through activation of Aurora B kinase (Kabil et al., 2008) , and that SFKs have been proposed to regulate cell proliferation through abrogation of p53 function (Broome and Courtneidge, 2000) . Interestingly, combined Src/MAPK signaling is also required for abscission during cytokinesis and cell derived from LSL-Kras G12D ;Pdx1-Cre tumors (activated Kras, wild-type Src; 'Kras') and LSL-Kras G12D ;CSK f/f ; Pdx1-Cre tumors (activated Kras and activated c-Src; 'Kras/Src') were implanted into the tail of the pancreas in 6-8-week-old male nu/nu mice. Tumors were allowed to establish for 7 days and then mice were administered vehicle or dasatinib (25 mg/kg, p.o., qd Â 14 d). At 21d, tumors were resected and weighed. Dasatinib treatment led to a significant reduction in burden of the Kras/Src, but not the Kras tumors; the symbol * indicates P ¼ 0.0019 compared with vehicle-treated mice; paired t-test (n ¼ 9 mice/treatment group). (c) Immunoblot analysis of activated Src levels in Kras/Src tumors following dasatinib treatment. Immunohistochemical analysis of p(Y418) Src (activated enzyme) demonstrated a reduction in Src activity in both the neoplastic ducts and surrounding stroma. Tumorbearing mice were dosed as in b above and the tumors were resected on day 14 at 1 h post dose for analysis by immunoblot and immunohistochemistry.
Oncogenic Ras/Src cooperativity DJ Shields et al proliferation (Kasahara et al., 2007) . Irrespective of the impact of dual Ras/Src signaling on suppressors of Kras-mediated tumorigenesis, these tumors exhibit an ongoing dependence on the hyperactivated Src signaling cascade. Accordingly, genetic or pharmacological Src inhibition attenuates the tumorigenicity of neoplastic cells from Ras/Src derived PDA's. In contrast, Morton et al. recently demonstrated that Src inhibition attenuated metastatic disease but not primary burden in the Ras/p53 mouse model (Morton et al., 2010) , suggesting that Src may have different roles in tumorigenesis or metastasis, depending on the underlying mutational context. Elucidation of the molecular basis for the differences in Src dependency could enable the identification of patient subsets that respond to therapeutic intervention with agents targeting the Src signaling pathways.
Materials and methods
Mouse strains CSK f/f (floxed), Lox-Stop-Lox (LSL)-Kras G12D and Pdx1-Cre mouse strains have been described (Schmedt et al., 1998; Jackson et al., 2001; Hingorani et al., 2003) . These strains were interbred to generate the compound triple mutant animals;
; Pdx1-Cre (KCC). All animal procedures were conducted in accordance with the appropriate regulatory standards under protocol S05018 as approved by the UCSD IACUC.
Histological and immunohistochemical analysis
All histological processing of fixed tumor specimens and staining (hematoxylin and eosin, periodic acid Schiff, alcian blue) of paraffin embedded sections was performed at the Histology Core in Moores UCSD Cancer Center. Histological analysis was performed by Dr David Tarin (Moores UCSD Cancer Center) and Dr Greg Boivin (Wright State University, Dayton, OH, USA). Immunostaining was performed according to the manufacturer's recommendations (Vector Labs, Burlingame, CA, USA), on 5 mM sections of paraffin-embedded tumors from the spontaneous mouse model or from human patients diagnosed with PDA (as approved by the Institutional Review Board at University of California, San Diego-Project#090407X). For pSFK(Y418/Y419) immunohistochemistry, antigen retrieval was performed in EDTA buffer pH 8.0. Antigen retrieval for all other antibodies was performed in citrate buffer, pH 6.0, at 95 1C for 20 min. Sections were treated with 0.3% H 2 O 2 for 30 min, blocked in normal goat serum, phosphate-buffered saline Tween 20 (PBS-T)-for 30 min followed by Avidin-D and then incubated overnight at 4 1C with primary antibody diluted in blocking solution as follows: CSK (AbCam, Cambridge, MA, USA, 1/100), pErk (Cell Signaling, Danvers, MA, USA, 1/500), CK19/TromaIII (Hybridoma bank, Iowa City, IA, USA, 1/1000), Ki67 (AbCam, 1/1000), Desmin (Neomarkers, Fremont, CA, USA, 1/500), Insulin (Invitrogen, Carlsbad, CA, USA, 1/10 000), Glucagon (Santa Cruz, Santa Cruz, CA, USA, 1/1000), Amylase (Sigma, St Louis, MO, USA , 1/100). Tissue sections were washed and then incubated with biotinylated secondary antibody (1:500, Jackson ImmunoResearch, West Grove, PA, USA) in blocking solution for 1 h. Sections were washed and incubated with Vectastain ABC (Vector Labs) for 30 min. Staining was developed using a Nickel-enhanced diamino-benzidine reaction (Vector Labs) and sections were counter-stained with hematoxylin.
Immunofluorescence analysis Cells were transfected with activated Src (SrcA) or control plasmids using Lipofectamine, and seeded directly on 22 mm coverslips in 6-well plates at a density of 1 Â 10 5 per well. Following incubation at 37 1C for 48 h, cells were fixed in cold methanol at À20 1C for 10 mins (a-tubulin, g-tubulin) or 4% paraformaldehyde/PBS, pH 7 at room temperature for 10 min. Following permeabilization with 0.2% Triton X-100/PBS for 2 min, cells were blocked in 3% bovine serum albumin/PBS for 1 h at room temperature, and then incubated with the primary antibodies (a-tubulin, g-tubulin, both AbCam; LaminB, Santa Cruz; all 1/300 dilution in 3% bovine serum albumin/PBS) at room temperature for 2 h. Cells were subsequently incubated for 1 h at room temperature with the appropriate species Alexa Fluor secondary antibodies (488 or 568). Nuclei were visualized following DraQ5 staining. Coverslips were mounted onto slides with Vectashield and images were acquired using laser scanning confocal microscopy under Â 60/1.4 NA oil objective (Nikon C1si, Nikon Instruments Inc., Melville, NY, USA). Quantification of MN was achieved by capturing images of multiple high-power fields and scoring the number of cells that contained discrete MN with a LaminB demarcated boundary. A minimum of 1000 cells were quantified per condition in each experiment and all experiments were performed three times. All images presented are single sections in the Z plane.
Imaging of tumor collagen content
Images of collagen content in hematoxylin and eosin-stained primary Kras/Src tumor sections were acquired with Cri's prototype 'Nubrio' imaging system, which enables the multispectral detection of birefingent structures such as collagen in tumor specimens. After setting the image acquisition parameters and taking appropriate background images for correct retardance and flat-fielding purposes, subsequent multimodal, multilayer images were acquired.
Immunoprecipitation and immunoblot analysis
Tumors/pancreata were homogenized by mechanical disruption. Both tissues and tumor cell lines were lysed in a modified radioimmuno precipitation assay buffer containing 50 mM Tris pH 7.5 at 41C, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM b-glycerophosphate, 1% NP-40, 1 mM Na3VO4, 0.25% sodium deoxycholate, 0.1% SDS, phosphatase and protease inhibitors (Roche, Indianapolis, IN, USA). Lysates were cleared by centrifugation and the protein concentration of the cleared lysate was determined by the bicinchoninic acid method. Immunoblots were performed using the following antibodies: pSFK-Y418 (Cell Signaling), Erk2, Fyn (Santa Cruz), Yes (BD Biosciences, San Diego, CA, USA), Src, pY-4G10 (Millipore, Billerica, MA, USA). Immunoprecipitations were performed with protein A/G beads and the Src, Yes and Fyn antibodies listed above.
Pancreatic tumor cell lines PDA cell lines were isolated as described (Aguirre et al., 2003) from primary tumors in the Kras/Src model. PDA lines used in this study from other spontaneous mouse models of pancreatic cancer have been described previously (Murphy et al., 2008; Thomas et al., 2008) . The PDA lines were maintained under standard culture conditions in RPMI medium 1640 supplemented with penicillin and streptomycin, 2mM glutamine and 10% fetal bovine serum. Proliferation rate of cell lines was determined by XTT assay (Promega, Madison, WI, USA), following 48 h incubation in complete media with vehicle (dimethyl sulfoxide) or the indicated dasatinib concentration.
